Cargando…

Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data

BACKGROUND: Pre-vaccination monocyte-to-lymphocyte ratio was previously suggested as a marker for malaria vaccine effectiveness. We investigated the potential of this cell ratio as a marker for malaria vaccine efficacy and effectiveness. Effectiveness was investigated by using clinical malaria endpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Nyandele, Jane Paula, Kibondo, Ummi Abdul, Issa, Fatuma, Van Geertruyden, Jean Pierre, Warimwe, George, Jongo, Said, Abdulla, Salim, Olotu, Ally
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501550/
https://www.ncbi.nlm.nih.gov/pubmed/37708143
http://dx.doi.org/10.1371/journal.pone.0291244
_version_ 1785106133750382592
author Nyandele, Jane Paula
Kibondo, Ummi Abdul
Issa, Fatuma
Van Geertruyden, Jean Pierre
Warimwe, George
Jongo, Said
Abdulla, Salim
Olotu, Ally
author_facet Nyandele, Jane Paula
Kibondo, Ummi Abdul
Issa, Fatuma
Van Geertruyden, Jean Pierre
Warimwe, George
Jongo, Said
Abdulla, Salim
Olotu, Ally
author_sort Nyandele, Jane Paula
collection PubMed
description BACKGROUND: Pre-vaccination monocyte-to-lymphocyte ratio was previously suggested as a marker for malaria vaccine effectiveness. We investigated the potential of this cell ratio as a marker for malaria vaccine efficacy and effectiveness. Effectiveness was investigated by using clinical malaria endpoint, and efficacy was investigated by using surrogate endpoints of Plasmodium falciparum prepatent period, parasite density, and multiplication rates in a controlled human malaria infection trial (CHMI). METHODS: We evaluated the correlation between monocyte-to-lymphocyte ratio and RTS,S vaccine effectiveness using Cox regression modeling with clinical malaria as the primary endpoint. Of the 1704 participants in the RTS,S field trial, data on monocyte-to-lymphocyte ratio was available for 842 participants, of whom our analyses were restricted. We further used Spearman Correlations and Cox regression modeling to evaluate the correlation between monocyte-to-lymphocyte ratio and Whole Sporozoite malaria vaccine efficacy using the surrogate endpoints. Of the 97 participants in the controlled human malaria infection vaccine trials, hematology and parasitology information were available for 82 participants, of whom our analyses were restricted. RESULTS: The unadjusted efficacy of RTS,S malaria vaccine was 54% (95% CI: 37%-66%, p <0.001). No correlation was observed between monocyte-to-lymphocyte ratio and RTS,S vaccine efficacy (Hazard Rate (HR):0.90, 95%CI:0.45–1.80; p = 0.77). The unadjusted efficacy of Whole Sporozoite malaria vaccine in the appended dataset was 17.6% (95%CI:10%-28.5%, p<0.001). No association between monocyte-to-lymphocyte ratio and the Whole Sporozoite malaria vaccine was found against either the prepatent period (HR = 1.16; 95%CI:0.51–2.62, p = 0.72), parasite density (rho = 0.004, p = 0.97) or multiplication rates (rho = 0.031, p = 0.80). CONCLUSION: Monocyte-to-lymphocyte ratio alone may not be an adequate marker for malaria vaccine efficacy. Further investigations on immune correlates and underlying mechanisms of immune protection against malaria could provide a clearer explanation of the differences between those protected in comparison with those not protected against malaria by vaccination.
format Online
Article
Text
id pubmed-10501550
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-105015502023-09-15 Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data Nyandele, Jane Paula Kibondo, Ummi Abdul Issa, Fatuma Van Geertruyden, Jean Pierre Warimwe, George Jongo, Said Abdulla, Salim Olotu, Ally PLoS One Research Article BACKGROUND: Pre-vaccination monocyte-to-lymphocyte ratio was previously suggested as a marker for malaria vaccine effectiveness. We investigated the potential of this cell ratio as a marker for malaria vaccine efficacy and effectiveness. Effectiveness was investigated by using clinical malaria endpoint, and efficacy was investigated by using surrogate endpoints of Plasmodium falciparum prepatent period, parasite density, and multiplication rates in a controlled human malaria infection trial (CHMI). METHODS: We evaluated the correlation between monocyte-to-lymphocyte ratio and RTS,S vaccine effectiveness using Cox regression modeling with clinical malaria as the primary endpoint. Of the 1704 participants in the RTS,S field trial, data on monocyte-to-lymphocyte ratio was available for 842 participants, of whom our analyses were restricted. We further used Spearman Correlations and Cox regression modeling to evaluate the correlation between monocyte-to-lymphocyte ratio and Whole Sporozoite malaria vaccine efficacy using the surrogate endpoints. Of the 97 participants in the controlled human malaria infection vaccine trials, hematology and parasitology information were available for 82 participants, of whom our analyses were restricted. RESULTS: The unadjusted efficacy of RTS,S malaria vaccine was 54% (95% CI: 37%-66%, p <0.001). No correlation was observed between monocyte-to-lymphocyte ratio and RTS,S vaccine efficacy (Hazard Rate (HR):0.90, 95%CI:0.45–1.80; p = 0.77). The unadjusted efficacy of Whole Sporozoite malaria vaccine in the appended dataset was 17.6% (95%CI:10%-28.5%, p<0.001). No association between monocyte-to-lymphocyte ratio and the Whole Sporozoite malaria vaccine was found against either the prepatent period (HR = 1.16; 95%CI:0.51–2.62, p = 0.72), parasite density (rho = 0.004, p = 0.97) or multiplication rates (rho = 0.031, p = 0.80). CONCLUSION: Monocyte-to-lymphocyte ratio alone may not be an adequate marker for malaria vaccine efficacy. Further investigations on immune correlates and underlying mechanisms of immune protection against malaria could provide a clearer explanation of the differences between those protected in comparison with those not protected against malaria by vaccination. Public Library of Science 2023-09-14 /pmc/articles/PMC10501550/ /pubmed/37708143 http://dx.doi.org/10.1371/journal.pone.0291244 Text en © 2023 Nyandele et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Nyandele, Jane Paula
Kibondo, Ummi Abdul
Issa, Fatuma
Van Geertruyden, Jean Pierre
Warimwe, George
Jongo, Said
Abdulla, Salim
Olotu, Ally
Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data
title Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data
title_full Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data
title_fullStr Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data
title_full_unstemmed Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data
title_short Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data
title_sort pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: a subgroup analysis of pooled clinical trial data
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501550/
https://www.ncbi.nlm.nih.gov/pubmed/37708143
http://dx.doi.org/10.1371/journal.pone.0291244
work_keys_str_mv AT nyandelejanepaula prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata
AT kibondoummiabdul prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata
AT issafatuma prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata
AT vangeertruydenjeanpierre prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata
AT warimwegeorge prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata
AT jongosaid prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata
AT abdullasalim prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata
AT olotually prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata